Online citations, reference lists, and bibliographies.
← Back to Search

Denosumab Significantly Increases DXA BMD At Both Trabecular And Cortical Sites: Results From The FREEDOM Study.

M. Bolognese, C. S. Teglbjærg, J. Zanchetta, K. Lippuner, M. Mcclung, M. Brandi, A. Høiseth, P. Lakatos, A. Moffett, R. Lorenc, Andrea Wang, C. Libanati
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased risk for fracture. In the FREEDOM study, denosumab reduced fracture risk and increased bone mineral density (BMD). We report the spine and hip dual-energy X-ray absorptiometry (DXA) BMD responses from the overall study of 7808 women and from a substudy of 441 participants in which more extensive spine and hip assessments as well as additional skeletal sites were evaluated. Significant BMD improvements were observed as early as 1 mo at the lumbar spine, total hip, and trochanter (all p<0.005 vs placebo and baseline). BMD increased progressively at the lumbar spine, total hip, femoral neck, trochanter, 1/3 radius, and total body from baseline to months 12, 24, and 36 (all p<0.005 vs placebo and baseline). BMD gains above the least significant change of more than 3% at 36 months were observed in 90% of denosumab-treated subjects at the lumbar spine and 74% at the total hip, and gains more than 6% occurred in 77% and 38%, respectively. In conclusion, denosumab treatment resulted in significant, early, and continued BMD increases at both trabecular and cortical sites throughout the skeleton over 36 mo with important gains observed in most subjects.
This paper references
10.1210/ENDO.141.9.7634
Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
N. Udagawa (2000)
The analysis of denosumab discontinuation and associated fracture incidence in the FREEDOM trial. Arthritis Rheum 63:S428
J Brown (2011)
2006 Denosumab in postmenopausal women with low bone mineral density
HG Bone
10.1002/jbmr.81
Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate
E. Seeman (2010)
10.1016/S1090-798X(09)79012-5
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
J. Dungan (2009)
10.1007/S12019-002-0028-6
Dual-energy X-ray absorptiometry in diagnosis of osteoporosis: Basic principles, indications, and scan interpretation
D. Theodorou (2002)
10.1210/jc.2010-2784
Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
S. Boonen (2011)
10.1016/j.jocd.2007.12.012
Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions.
D. Hans (2008)
mineral density
M McClung (2011)
10.1016/j.bone.2008.04.007
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
P. Miller (2008)
10.1002/jbmr.251
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
R. Eastell (2011)
10.1016/S1090-798X(10)79366-8
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
J. Dungan (2010)
The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: a distinctive attribute of denosumab therapy [abstract 1064
E Seeman (2011)
Effects of denosumab on radius BMD, strength, and wrist fractures: results from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) study [abstract 1062
J Simon (2011)
2010 Effects of denosumab on bone histomorphometry : the FREEDOM and STAND stud
MR McClung
10.2214/AJR.10.5416
Dual-energy x-ray absorptiometry in the diagnosis of osteoporosis: a practical guide.
R. Lorente-Ramos (2011)
10.1016/J.YEND.2012.03.031
Relationship Between Bone Mineral Density Changes With Denosumab Treatment and Risk Reduction for Vertebral and Nonvertebral Fractures
B. Clarke (2012)
10.1002/jbmr.149
Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
I. Reid (2010)
2000 Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo
DL Lacey (1998)
Denosumab in postmenopausal women with low bone mineral density.
W. Rifkin (2006)
10.1210/jc.2007-2814
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Henry G. Bone (2008)
10.1002/jbmr.119
Efficacy and safety of a once‐yearly i.v. Infusion of zoledronic acid 5 mg versus a once‐weekly 70‐mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double‐blind, active‐controlled study
E. Orwoll (2010)
The analysis of denosumab discontinuation and associated fracture incidence in the FREEDOM trial
S Boonen (2011)
10.1016/J.JOCD.2006.11.001
Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis.
G. Blake (2007)
10.1016/S0002-9440(10)64556-7
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
D. Lacey (2000)
density and turnover in postmenopausal women with low bone mass after long - term continued , discontinued , and restarting of therapy : a randomized blinded phase 2 clinical trial
PD Miller (2011)
10.1016/S0092-8674(00)81569-X
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation
D. Lacey (1998)
10.1073/PNAS.95.7.3597
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.
H. Yasuda (1998)
10.1210/jc.2010-1805
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
P. Miller (2011)
2011 Effects of denosumab on bone turnover markers in postmenopausal osteoporo
R Marcus
10.1359/jbmr.0809010
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown (2009)
10.1016/S0140-6736(09)60250-6
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
D. Reid (2009)
2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis
R Lorente-Ramos (2011)
10.1016/j.bone.2010.04.594
Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
H. Genant (2010)
Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial [abstract 1061
M McClung (2011)



This paper is referenced by
10.1016/B978-0-12-801238-3.66148-2
Osteoporosis, Treatment: Sequential and Combination Therapy
Benjamin Z Leder (2014)
10.1016/j.jmbbm.2016.03.010
Prediction of denosumab effects on bone remodeling: A combined pharmacokinetics and finite element modeling.
R. Hambli (2016)
10.1007/978-1-4899-7436-5_12
Newer Adult Bone Drugs
Natalie E Cusano (2014)
10.1007/s40610-016-0037-3
Mouse Models in Bone Fracture Healing Research
M. Haffner-Luntzer (2016)
10.1007/978-3-662-45698-9_63
Treatment and Prevention of Glucocorticoid-Induced Osteoporosis
R G Micheletti (2015)
10.1002/jcph.228
Similar Relationship Between the Time Course of Bone Mineral Density Improvement and Vertebral Fracture Risk Reduction With Denosumab Treatment in Postmenopausal Osteoporosis and Prostate Cancer Patients on Androgen Deprivation Therapy
J. P. Perez Ruixo (2014)
10.1007/s00198-019-05020-8
Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group
J. P. Bilezikian (2019)
10.1002/jbm4.10191
Denosumab Treatment Improved Health‐Related Quality of Life in Osteoporosis: A Prospective Cohort Study
S. Hayashi (2019)
10.1007/s40266-018-0525-7
Denosumab: A Review in Postmenopausal Osteoporosis
E. Deeks (2018)
10.1007/978-1-4899-7436-5
Bone Drugs in Pediatrics
G. Klein (2014)
10.23970/AHRQEPCCER218
Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review
Howard A Fink (2019)
10.2214/AJR.10.5416
Dual-energy x-ray absorptiometry in the diagnosis of osteoporosis: a practical guide.
R. Lorente-Ramos (2011)
10.1007/s00223-018-0394-4
Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis
A. Popp (2018)
10.1016/J.FINEL.2015.04.007
A microscale bone remodeling simulation method considering the influence of medicine and the impact of strain on osteoblast cells
W. Yi (2015)
Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women
(2019)
10.1007/s00223-020-00754-8
A Simple-to-Use Score for Identifying Individuals at High Risk of Denosumab-Associated Hypocalcemia in Postmenopausal Osteoporosis: A Real-World Cohort Study.
K. H. Kim (2020)
10.1007/s11914-015-0295-7
How Long to Treat with Denosumab
A. G. Costa (2015)
10.1016/j.knee.2019.12.010
Denosumab prevents periprosthetic bone mineral density loss in the tibial metaphysis in total knee arthroplasty.
Y. Murahashi (2020)
10.1016/j.bone.2015.06.025
Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology.
P. Zysset (2015)
10.1007/s40520-013-0086-x
Effects of denosumab on cortical and trabecular microarchitecture: evidences from clinical studies
G. Iolascon (2013)
10.1016/j.afos.2016.12.001
Bone turnover rate and bone formation/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change
S. Nakatoh (2017)
10.1177/1759720X15579189
Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis
O. Törring (2015)
10.3949/ccjm.82a.13173
Denosumab: A novel antiresorptive drug for osteoporosis
E. Suresh (2015)
10.1016/j.ando.2015.10.009
Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.
D. Diédhiou (2015)
10.3748/wjg.v26.i33.4960
Effects of denosumab treatment in chronic liver disease patients with osteoporosis
Chisato Saeki (2020)
10.1007/s00198-015-3179-x
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
S. Ferrari (2015)
10.3109/09513590.2014.892067
The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab
A. Capozzi (2014)
10.1016/j.ecl.2016.11.001
Novel Therapies for Postmenopausal Osteoporosis.
L. Bandeira (2017)
10.1007/s00198-018-4624-4
Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling
R. Winzenrieth (2018)
10.1007/978-3-319-69287-6_18
Combination and Sequential Osteoanabolic/Antiresorptive Therapy in Osteoporosis Treatment
Benjamin Z. Leder (2020)
10.1007/s40266-014-0191-3
Denosumab: A Review of its Use in Postmenopausal Women with Osteoporosis
L. Scott (2014)
10.1177/1759720X15579189
Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis.
Ove Tørring (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar